An observational study in Atrial Fibrillation, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Atrial Fibrillation with a site in Russia — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Russia.
Among the 20 studies in Atrial Fibrillation with a site in Russia, this one is the only one that started in 2015, is one of 8 observational ones, reaches primary completion later than 0 of the 11 other live ones, and was the 5th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →9 of the 20 studies in Atrial Fibrillation with a site in Russia are open now. Recruiting first, the newest first:
Bakulev Scientific Center of Cardiovascular Surgery · Sites in Russia
Ages 18–70
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 18+
Bakulev Scientific Center of Cardiovascular Surgery · Sites in Russia
Ages 18–80
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Ages 18–80
Bakulev Scientific Center of Cardiovascular Surgery · Sites in Russia
Ages 60–90
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 158 across the 11 interventional studies, 1,600 across the 8 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
6 of the studies in Atrial Fibrillation with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253000Bakulev Scientific Center of Cardiovascular SurgeryRadiofrequency and Cryoablation of the Posterior Wall of the Left Atrium | 2026-12-30 |
| NCT06540352National Medical Research Center for Cardiology, Ministry of Health of Russian FederationA Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form | 2026-12-31 |
| NCT04347187National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-2 | 2026-12-31 |
| NCT07487714Tomsk National Research Medical Center of the Russian Academy of SciencesComparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration | 2027-05 |
| NCT07063381Bakulev Scientific Center of Cardiovascular SurgeryLow-frequency Electrical Stimulation for Cognitive Enhancement in Atrial Fibrillation | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies in Atrial Fibrillation with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with atrial fibrillation
Hospitalized or outpatients with confirmed atrial fibrillation and CHA2DS2VASC > 1
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral anticoagulants, dual or triple antithrombotic theraphy
Also known as: antiplatelets
composite of major cardiovascular events
stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cqrdiac death
Time frame: unclusion up to 5 years
composite of any bleeding events
major, clinically relevant nonmajor, minor (BARC, ISTH,GARFIELD AF)
Time frame: unclusion up to 5 years
Mutations in following genes
CYP2C9\*, VKORC1
Time frame: inclusion
Plan to share: Yes — Individual participant data that underlie the results reported in the article after deidentification (text, tables, figures)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 9 months and ending 36 months following publication
Access criteria: Researchers who provide a methodologically sound proposal . For individual participant data meta-analysis.
Started Jan 2015 (actual). Primary completion is estimated for Dec 2026, 143 months after the start.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 143 months is above that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation